Healthcare Industry News: metabolic disease
News Release - July 24, 2007
Cerenis Therapeutics Announces the Addition of Three Pharmaceutical Industry Veterans to its Management TeamNarendra D. Lalwani, Ph.D., M.B.A., Constance Keyserling, M.S., and John Wetterau, Ph.D. bring a wealth of clinical, R&D and operations experience to Cerenis
TOULOUSE, France and ANN ARBOR, Mich., July 24 (HSMN NewsFeed) -- Cerenis Therapeutics SA (Cerenis), a privately held pharmaceutical company developing novel HDL therapies to treat cardiovascular and metabolic diseases, today announced the expansion of its management team to include three pharmaceutical industry veterans. With more than half a century of combined industry experience, Narendra D. Lalwani, Ph.D., M.B.A., Constance Keyserling, M.S., and John Wetterau, Ph.D. have had outstanding success bringing breakthrough therapies for cardiovascular diseases from discovery to late-stage clinical development.
Dr. Lalwani joins Cerenis as chief scientific officer. With more than 18 years of experience in pharmaceutical R&D, Dr. Lalwani is an expert in cardiovascular and metabolic disorders who has played leading roles in key development programs at Parke-Davis, Esperion and Pfizer. Most recently Dr. Lalwani was the senior director and head of drug safety evaluation at Esperion Therapeutics, a Pfizer Inc. company, where he led preclinical research in toxicology, pharmacokinetics and drug metabolism. Prior to the acquisition of Esperion by Pfizer, Dr. Lalwani was vice president of drug safety evaluation and played key leadership roles in the development of all HDL therapy candidates at Esperion, including ETC-216 (Apo-A1 Milano), and a range of novel chemical entities that promote reverse lipid transport through HDL elevation.
As Cerenis' vice president of clinical development and operations since December 2006, Ms. Keyserling has been instrumental in the design and management of the company's development programs. Ms. Keyserling's more than 20 years of international clinical development experience includes leadership positions at Parke-Davis, Pfizer, Esperion, and most recently QuatRx, where she served as vice president of development operations. Previously she was director of clinical operations for Pfizer Global Research and Development. At Parke-Davis, Ms. Keyserling's responsibilities spanned biometrics and anti- infective clinical development in the United States and Europe.
Dr. John Wetterau joins Cerenis as the company's vice president of pharmacology. With more than 16 years of pharmaceutical discovery and development experience, Dr. Wetterau has conducted groundbreaking research in the field of cardiovascular diseases. Most recently, Dr. Wetterau was a research fellow at the department of cardiovascular pharmacology at Pfizer in Ann Arbor, Michigan, conducting research focused on dyslipidemia/atherosclerosis drug discovery. Previously, Dr. Wetterau was executive director of the department of metabolic research at Bristol-Myers Squibb where he led in the discovery of drugs to treat diabetes, obesity and dyslipidemia.
"Narendra, Connie and John bring deep scientific and development expertise to the Cerenis team," said Jean-Louis Dasseux, Ph.D., M.B.A., president and CEO of Cerenis. "We welcome them and are fortunate to have them as part of our management team. Their talents and experiences will be essential elements of our success as we continue to advance multiple product candidates to clinical development."
About Cerenis Therapeutics
Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL therapies for the treatment of cardiovascular and metabolic diseases. Based on pioneering research conducted by Cerenis' team of world leaders in HDL therapy, the company is pursuing a range of HDL product candidates that are positioned to represent major advances in patient care and significant commercial opportunities in the treatment of cardiovascular and metabolic diseases. Cerenis has operations in Toulouse, France and Ann Arbor, Michigan. For more information please visit www.cerenis.com.
Source: Cerenis Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.